Streetbeat News

Revenues

SE

Recent analyst evaluations of Sea (NYSE:SE) show diverse outlooks, with a notable increase in the average 12-month price target to $69.12 from $53.86. Sea, operating Southeast Asia's largest e-commerce platform, Shopee, and gaming business, Garena, has shown positive revenue growth but faces challenges in net margin and ROA. The company's financial health is highlighted by its market capitalization and debt management.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 8:00 pm

MAG

MAG Silver reported Q1 earnings of $0.14 per share, surpassing the consensus estimate of $0.13, marking a 180% increase from last year's $0.05. Sales rose 46.63% YoY to $827K.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 7:42 pm

SAM

STZ

TAP

Jefferies analyst Kaumil Gajrawala upgraded Boston Beer Company (SAM) to Buy, raising the price target to $360. The upgrade is based on expectations of stabilized business through marketing and reduced SKU complexity, easing supply chain costs, and potential for capital returns due to a clean balance sheet. Gajrawala also adjusted ratings and targets for Constellation Brands (STZ) and Molson Coors Beverage Company (TAP), citing various factors including sales outlook and market trends.

Portfolio Pulse from Nabaparna Bhattacharya

May 14, 2024 | 7:40 pm

NI

NiSource (NYSE:NI) received all somewhat bullish ratings from analysts in the last quarter, with an updated average 12-month price target of $30.75, reflecting a 4.24% increase from the previous target. Analysts from Barclays, Evercore ISI Group, and BMO Capital raised their price targets, indicating positive sentiment towards NiSource's market performance despite its revenue decline and lower market capitalization.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 7:01 pm

CAPR

Capricor Therapeutics (NASDAQ:CAPR) has seen diverse analyst ratings over the last three months, with a recent shift towards more bullish outlooks. The average 12-month price target has increased to $30.6, up from $24.00, indicating a positive sentiment shift. The company, focusing on biological therapies for diseases like Duchenne muscular dystrophy, has shown impressive financial performance with significant revenue growth and strong profitability metrics.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 7:01 pm

FOLD

Amicus Therapeutics (NASDAQ:FOLD) has received mixed reviews from 6 financial analysts over the past quarter, with ratings ranging from bullish to bearish. The average 12-month price target is $17.5, with a high of $22.00 and a low of $13.00, marking a 6.67% decline from the previous average. Analysts have adjusted their ratings and price targets, reflecting their latest views on the company's performance and market conditions. Amicus Therapeutics is a biotech company focused on rare metabolic diseases, showing strong market position, revenue growth, and financial performance despite some challenges in ROE and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 7:00 pm

AMGN

Senator Dick Durbin has accused Amgen (AMGN) of prioritizing profits over patient care by recommending a higher-than-necessary dose for its cancer drug, Lumakras. Durbin's allegations suggest that Amgen's dosing recommendations are not in the best interest of patients, potentially leading to higher costs and increased side effects without additional benefits. This criticism comes amid broader concerns over drug pricing and pharmaceutical practices.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 6:55 pm

AAPL

GOOGL

META

KeyBanc analyst Justin Patterson reiterated a Buy rating on Alphabet Inc (NASDAQ:GOOGL) with a $200 price target, highlighting the potential of AI innovations and new monetization opportunities at the upcoming Google I/O 2024. Patterson emphasizes Alphabet's scale and AI's role in creating new revenue streams, particularly through the integration of Gemini across Google products. He anticipates updates on Android 15, Wear OS, search generative experience, and Cloud, all powered by Gemini. Patterson also notes Alphabet's consistent revenue growth in digital advertising and the potential for monetizing non-advertising services.

Portfolio Pulse from Anusuya Lahiri

May 14, 2024 | 6:05 pm

MITK

Analyst ratings for Mitek Systems (NASDAQ:MITK) show a positive shift with all 4 analysts giving bullish ratings in the last three months. The average 12-month price target has been raised to $19.00, indicating an 11.76% increase from the previous target of $17.00. Mitek Systems, a software development company specializing in mobile imaging and AI, faces revenue challenges with a -19.22% decline over 3 months but maintains a strong market presence with its innovative solutions.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 6:01 pm

CRWD

In the last three months, 46 analysts have published ratings on CrowdStrike Holdings (CRWD), with a shift towards more bullish sentiments. The average 12-month price target is now $390.85, marking an 18.62% increase from the previous target. Analysts from firms like JMP Securities, Keybanc, and Morgan Stanley have adjusted their ratings and price targets, reflecting optimism about CrowdStrike's future performance. The company's financials show a strong revenue growth rate of 32.63% as of January 31, 2024, but it faces challenges in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 6:01 pm